A
AgilentDNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Q1 company results were constructive: Agilent reported 4.4% core growth and raised FY2026 revenue and EPS guidance, which leaves room for the stock to rerate if Q2 confirms that momentum and the Biocare deal closes on time [#IR-2026-02-25][#PR-2026-03-09].
Posture
Defensive
Lead driver
Value
What changed
8 setup hits (3d) with net bullish as of 2026-06-02.
What can break
Biocare still needs regulatory approvals and integration execution, and EPS accretion is not expected until roughly 12 months after close [#PR-2026-03-09].
Momentum
47
Value
62
Sentiment
33
Setup hits (3d)
8 · Net Bullish
AI TargetsBase $116.00 · Bull $132.00 · Bear $96.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-18 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Bullish
Target $162.29
Why
Momentum47 · Δ7d +24.5
Value62 · Δ7d -0.7
Sentiment33 · Δ7d -12.9
So what
Weak posture (Net Bullish). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
47
34% active weight
Current posture
7d trendImproving
Δ7d
+24.5
Δ21d
+27.3
Value
62
32% active weight
Current posture
7d trendFlat
Δ7d
-0.7
Δ21d
-0.4
Sentiment
33
33% active weight
Current posture
7d trendSoftening
Δ7d
-12.9
Δ21d
-17.8
Why this grade
Composite grade D. Momentum 46.9 / Value 61.7 / Sentiment 32.6
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$38.43B
Beta
1.30
Shares Out
283.5M
P/E (TTM)
31.3
P/S (TTM)
5.83
P/FCF (TTM)
46.58
Rev YoY
+9.4%
EPS YoY
+23.6%
Gross Margin
+52.7%
Op Margin
+21.3%
Net Debt
$1.57B
Current Ratio
1.96
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology